ClinicalTrials.gg
Status unknownNCT01947569Updated Oct 23, 2013

Dendritic Cells for Type 1 Diabetes Mellitus (T1DM) Therapy

A Phase 1/2 interventional study of Biological in Treatment of Type I Diabetes Mellitus., sponsored by DiaVacs, Inc.. Status unknown at 1 site in United States. Open to participants aged 12 Years to 35 Years. Per ClinicalTrials.gov, last updated 2013-10-23.

Sponsored by DiaVacs, Inc. · Phase 1/2, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Oct 2013), so the status shown — last known as Not yet recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
90
Allocation
Randomized
Ages
12 Years to 35 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 3,022 studies in Diabetes Mellitus with a site in United States — 289 open to participants now, 389 under way, 12 of them phase 3. Diabetes Mellitus · United States.

Planned enrollment
1,190th of 2,501
90 · median 82
Started
2013
with 144 others
Phase 1/2
58 of 3,022
5 open now
Registered
1,532nd of 3,022
by date

Among the 3,022 studies in Diabetes Mellitus with a site in United States, this one is the 1,190th largest by planned enrollment of the 2,501 interventional ones that give a count, is one of 145 that started in 2013, is one of 58 in phase 1/2, and was the 1,532nd registered.

Diabetes Mellitus

8,293 studies on the registry are indexed under Diabetes Mellitus; 1,072 are open to participants now.

Browse Diabetes Mellitus studies →

Open to participants now

289 of the 3,022 studies in Diabetes Mellitus with a site in United States are open now. Recruiting first, the newest first:

284 more — sign in →

All 289 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 648 Diabetes Mellitus studies recruiting now, 357 (55%) set no upper age limit and 195 (30%) stop at 75 or younger; 88 take children under 18; 182 take healthy volunteers.

This study: 12 Years to 35 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 3,022 studies in Diabetes Mellitus with a site in United States, or all of them as a file.
02

Study summary

Phase IB will evaluate the safety of autologous, ex vivo-engineered, co-stimulation impaired dendtritic cells to maintain and improve functional residual beta cell mass in new onset Type I Diabetes Mellitus (T1DM) patients. Efficacy measures will be collected and summarized.

Phase IIA will evaluate the safety and efficacy of 3 randomized treatment groups in new onset T1DM patients to assess if the antisense DNA-treated co-stimulation-impaired immunoregulatory dendritic cells (iDC) will safely preserve and/or increase B-cell mass resulting in improvement and/or normalization of blood glucose levels and glycated hemoglobin A1c.

03

Conditions studied

  • Treatment of Type I Diabetes Mellitus.

Browse trials for

04

Who can participate

Ages eligible
12 Years to 35 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria:(both open label phase IB safety and Phase IIA study):

  1. Patients with new onset T1DM (>18 years of age for the phase IB and then >16 (first 10 subjects), >12 years of age for the second 10 subjects, > 8 years for the next 10 subjects and, finally, >8 years of age for the remainder of the phase IIA patients) within 6 months of diabetes mellitus diagnosis.
  2. Evidence of decreased β-cell function as measured by C-peptide and blood glucose levels consistent with impaired glucose tolerance.
  3. Evidence of at least one high-risk HLA haplotype.
  4. Evidence of at least one diabetes-related autoantibody (e.g. IA-2, GAD, ZnT8) ,
  5. Adequate immune competence as assessed by immunoreactivity to alloantigens in mixed leukocyte culture and reactivity to viral antigens (CEF Pool Assay) in vitro.
  6. Normal hematologic, liver and kidney function.
  7. Female participants of in this study must agree to use an effective form of during study participation. Reliable and effective forms of birth control include: true abstinence, intrauterine device (IUD), hormonal-based contraception, double-barrier contraception [condom or occlusive cap (diaphragm or cervical cap) with spermicide], or surgical sterilization (vasectomy for male partner, tubal ligation or hysterectomy). Sexually active male participants must agree to use an effective form of birth control such as condoms.

Exclusion Criteria:(both open label phase IB safety and Phase IIA study):

  1. Enrollment or history of enrollment in a drug, or biologic therapy study sponsored by TrialNet.
  2. A significant history or current evidence of cardiac disease, uncontrolled hypertension, serious arrhythmias.
  3. Evidence of active infection requiring antibiotic therapy.
  4. History of other concurrent significant medical diseases.
  5. Pregnant or lactating women.
  6. Patients requiring chronic systemic .
  7. Any other immune disorder including but not limited to other diseases, , , , HPV, HSV positivity.
  8. Impaired renal function with a creatinine level > 1.5.
  9. Administration of the following therapies while patients are undergoing treatment on this protocol: i) radiation therapy; ii) chemotherapy; iii) corticosteroids (except when administered in life-threatening circumstances); iv) other particle or cell-based therapies; v) other biologic therapies; vi) other therapies aimed at modulating the immune system; vii) other endocrine-related therapies, hormone replacement (other than thyroxine and contraceptive), glucoregulation.
  10. A hemaglobinopathy known to interfere with the ability to accurately determine .
  11. No prior radiation therapy, immunotherapy, or chemotherapy.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
90 participants (estimated)

Study arms

  • Experimental
    iDC recipients

    iDC cells modified by in vitro engineering.

    Biological: Biological

  • Active comparator
    Control DC recipients

    DC cells which have not been modified.

    Biological: Biological

  • Placebo comparator
    Placebo recipients

    Saline injections.

    Biological: Biological

Interventions

06

What researchers measure

Primary outcomes

  1. The incidence of treatment-emergent adverse events.

    Time frame: Month 12

Secondary outcomes

  1. 2-hour area under the curve (AUC) average of C-peptide at 12 months after completion of administration of assigned therapy (Protocol Month 15).

    Time frame: 12 Months

07

Study locations

1 site
  • UPMC
    Pittsburgh, Pennsylvania 15213, United States
    • Mary Korytokowski, MD · Principal investigator
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2013 and a primary completion of Nov 2014. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 18, 2013
First posted
Sep 20, 2013
Start
Oct 2013
Primary completionEst.
Nov 2014
Last update
Oct 23, 2013
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 23, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01947569
Lead sponsor
DiaVacs, Inc.
Responsible party
Sponsor
First posted
Sep 20, 2013
Start date
Oct 2013
Primary completion
Nov 2014 (estimated)
Last update
Oct 23, 2013

Study contacts

Orville G. Kolterman, MD
Contact
okolterman@alumnistandford.edu
7242085707
Peter Gregoire, MBA
Contact
pgregoire@futurelifesourcesllc.org
7242085707

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Oct 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Biological Products

Start the discussion